Doxorubicin encapsulated liposome. Lipo-Dox® has been approved by the Department of Health (DOH) in Taiwan for the treatment of breast cancer ovarian cancer, and AIDS-related Kaposi's sarcoma.
- ✔ Category
- ✔ Application
- ✔ Collaboration Option
- ✔ Target Market
➤ Distribution & Dealership
➤ East Asia (JPN，KOR， TWN)
➤ South Asia (IND & Neighbors)
Request for Collaboration
Lipo-Dox® is liposomally encapsulated doxorubin which was approved by the Department of Health in Taiwan for the treatment of breast cancer, ovarian cancer, and AIDS-related Kaposi's sarcoma. Lipo-Dox has been licensed to TTY for manufacturing and distribution.
- Effectively reduce the side effects of drugs
- Broadened indications
In accordance with Taiwan National Health Insurance reimbursement:
- As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
- Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens.
- Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa, skin & internal organs.
People who like this also like